Nasus Pharma Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.3%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$1.48next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Expected Initiation of NS002 Pivotal Clinical Study | 31 Dec 2026 |
| Expected Top-line Results from NS002 Pivotal Study | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
NS002 Epinephrine Plasma Threshold Achievement at 5 Minutes Annually88.4Target: Superiority or non-inferiority to EpiPen (64.6%) in pivotal study
Cash Runway Sufficiency Quarterly15MTarget: Sufficient to fund operations through Q2 2027
NS002 Median Time to 100 pg/mL Epinephrine Threshold (T100) Annually1.7Target: Statistically significant faster onset than EpiPen (3.42 minutes)
Watch Items
- NS002 Pivotal Study InitiationTrigger: Initiation of the pivotal clinical trial in Q4 2026Action: Monitor regulatory alignment with the FDA and clinical site readiness in the US/Canada.
- NS003 First-in-Human PK StudyTrigger: Initiation of Phase 1 PK study in Q3 2026Action: Review initial safety, tolerability, and pharmacokinetic data to validate the Nasax platform for ondansetron.
- Going Concern Risk and Additional Capital RequirementsTrigger: Cash reserves falling below $5 million without additional non-dilutive or equity fundingAction: Evaluate capital raising options, strategic partnerships, or licensing agreements for paused assets like NS001.
Research as of 19 Jun 2026